Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
about
How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillationDabigatran-Associated Intracranial Hemorrhage: Literature Review and Institutional ExperienceGuidance for the practical management of warfarin therapy in the treatment of venous thromboembolismNew oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplastySpontaneous rectus sheath hematoma in a patient treated with apixaban.A Review of the Toxicity of HIV Medications II: Interactions with Drugs and Complementary and Alternative Medicine ProductsThe challenges and limitations of widespread direct oral anticoagulant treatment: practical suggestions for their best use.Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs.Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects.Decreased Rivaroxaban Levels in a Patient with Cerebral Vein Thrombosis Receiving PhenytoinChecklists for the use of novel oral anticoagulants by the front-line clinician.Miconazole buccal gel and risk for systemic bleeding: how certain topical formula can interfere with anticoagulants.Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact.Apixaban Concentration with and without Coadministration of Carbamazepine: A Case with No Apparent Interaction.Potential drug-drug interactions with direct oral anticoagulants in elderly hospitalized patients.Atrial Arrhythmias in Pulmonary Hypertension: Pathogenesis, Prognosis and Management.Practical perspectives on the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation: A view from the Middle East and North Africa.Effect of ABCB1 genetic polymorphisms on the transport of rivaroxaban in HEK293 recombinant cell lines.Validation of an LC–MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma
P2860
Q26776413-A1A0C22D-EC82-419B-AF20-5A884E56A69DQ26783457-DACCC5B3-EAEF-4AD4-B916-0B2E5B79DC5FQ28066527-22CC7F98-5EDB-46F7-AF5A-03978F814E37Q33891915-E0111274-F7E8-45AF-BD81-61D14C8450B4Q36601314-B0CF9E95-554B-4C8B-8474-9B9F97980485Q38513275-6790A944-FEC1-40F9-9006-C3B7E06A32C1Q38664920-E1165D94-F4EF-47A0-B9BB-E5B89D2D4EFDQ38687974-BDBF499F-3DCC-4E34-B7ED-1527C0FC1E86Q39310587-CAE3CEDF-4163-4253-BFA9-6EEBC31F355EQ41509586-AB70E708-89CB-4CEA-A4D0-89DDF0C064EEQ43117540-C9B9A904-3659-49E4-A21B-AFB568831058Q49040124-9876F204-D7AB-4DCD-AF61-BD53DB1EACB4Q49171317-56970A7C-C1A4-473C-BFC7-675CB1263335Q49335499-02E54B2B-6310-4A1B-BA1A-0CDE75ACAD2FQ53076704-D01AF5CD-28BE-417F-B151-D99A08973CC0Q55036898-EAA49A87-5F05-4545-8A54-AE4D61A35F34Q55222788-98A76A82-1DB9-4A03-A873-C4F4154C6905Q55662488-457D4A75-09DE-4061-8310-AC2EA6DD6202Q58420626-244921C9-6A2D-4335-8D50-C0D17D6B0910
P2860
Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Pharmacokinetic and pharmacody ...... ents with atrial fibrillation?
@en
type
label
Pharmacokinetic and pharmacody ...... ents with atrial fibrillation?
@en
prefLabel
Pharmacokinetic and pharmacody ...... ents with atrial fibrillation?
@en
P356
P1476
Pharmacokinetic and pharmacody ...... ents with atrial fibrillation?
@en
P2093
Michael Gulseth
Thaddaus Hellwig
P304
P356
10.1177/1060028013504741
P407
P577
2013-10-09T00:00:00Z